HER-2/neu and fibrinolytic factors in human breast cancer

S. Tommasi, C. Rella, C. Giannella, M. Quaranta, F. Schittulli, A. Paradiso, M. Coviello, M. De Lena

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

HER-2/neu status and t-PA, u-PA, and PAI-1 cytosol content were evaluated in 88 primary breast cancer patients to determine the relationships between these parameters. HER-2/neu was amplified in 24% (20/84) of tumor samples and overexpressed in 28% (14/50). In the overall series, median t-PA, u-PA and PAT-1 contents, measured by the enzyme-linked immunoassay (ELISA), resulted in 1.7, 1.1 and 1.0 ng/mg cytosol protein (cyt prot), respectively. HER-2/neu overexpressed cases showed higher u-PA levels than those normally expressed whereas t-PA and PAI-1 levels did not vary in HER-2/neu altered and non altered cases. The t-PA levels did not differ in cases with or without HER-2/neu alterations, when separately considering the node-negative and node-positive cases. A significant relationship between t-PA levels and HER-2/neu alterations was observed only in the ER+ tumors: t-PA levels were lower in amplified and overexpressed cases (1.4 versus 2.5 ng/mg cyt prot in amplified and single copy gene, respectively; 1.6 versus 2.3 ng/mg cyt prot in overexpressed and normally expressed cases, respectively). Therefore, t-PA and HER-2/neu could provide additional prognostic information for ER-negative patients.

Original languageEnglish
Pages (from-to)473-477
Number of pages5
JournalInternational Journal of Oncology
Volume5
Issue number3
Publication statusPublished - 1994

Fingerprint

Cytosol
Breast Neoplasms
Plasminogen Activator Inhibitor 1
Proteins
Immunoenzyme Techniques
Neoplasms
Genes

Keywords

  • Breast cancer
  • Fibrinolytic factors
  • HER-2/neu

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tommasi, S., Rella, C., Giannella, C., Quaranta, M., Schittulli, F., Paradiso, A., ... De Lena, M. (1994). HER-2/neu and fibrinolytic factors in human breast cancer. International Journal of Oncology, 5(3), 473-477.

HER-2/neu and fibrinolytic factors in human breast cancer. / Tommasi, S.; Rella, C.; Giannella, C.; Quaranta, M.; Schittulli, F.; Paradiso, A.; Coviello, M.; De Lena, M.

In: International Journal of Oncology, Vol. 5, No. 3, 1994, p. 473-477.

Research output: Contribution to journalArticle

Tommasi, S, Rella, C, Giannella, C, Quaranta, M, Schittulli, F, Paradiso, A, Coviello, M & De Lena, M 1994, 'HER-2/neu and fibrinolytic factors in human breast cancer', International Journal of Oncology, vol. 5, no. 3, pp. 473-477.
Tommasi S, Rella C, Giannella C, Quaranta M, Schittulli F, Paradiso A et al. HER-2/neu and fibrinolytic factors in human breast cancer. International Journal of Oncology. 1994;5(3):473-477.
Tommasi, S. ; Rella, C. ; Giannella, C. ; Quaranta, M. ; Schittulli, F. ; Paradiso, A. ; Coviello, M. ; De Lena, M. / HER-2/neu and fibrinolytic factors in human breast cancer. In: International Journal of Oncology. 1994 ; Vol. 5, No. 3. pp. 473-477.
@article{238d95c2b05f4df2a4299326de7179e0,
title = "HER-2/neu and fibrinolytic factors in human breast cancer",
abstract = "HER-2/neu status and t-PA, u-PA, and PAI-1 cytosol content were evaluated in 88 primary breast cancer patients to determine the relationships between these parameters. HER-2/neu was amplified in 24{\%} (20/84) of tumor samples and overexpressed in 28{\%} (14/50). In the overall series, median t-PA, u-PA and PAT-1 contents, measured by the enzyme-linked immunoassay (ELISA), resulted in 1.7, 1.1 and 1.0 ng/mg cytosol protein (cyt prot), respectively. HER-2/neu overexpressed cases showed higher u-PA levels than those normally expressed whereas t-PA and PAI-1 levels did not vary in HER-2/neu altered and non altered cases. The t-PA levels did not differ in cases with or without HER-2/neu alterations, when separately considering the node-negative and node-positive cases. A significant relationship between t-PA levels and HER-2/neu alterations was observed only in the ER+ tumors: t-PA levels were lower in amplified and overexpressed cases (1.4 versus 2.5 ng/mg cyt prot in amplified and single copy gene, respectively; 1.6 versus 2.3 ng/mg cyt prot in overexpressed and normally expressed cases, respectively). Therefore, t-PA and HER-2/neu could provide additional prognostic information for ER-negative patients.",
keywords = "Breast cancer, Fibrinolytic factors, HER-2/neu",
author = "S. Tommasi and C. Rella and C. Giannella and M. Quaranta and F. Schittulli and A. Paradiso and M. Coviello and {De Lena}, M.",
year = "1994",
language = "English",
volume = "5",
pages = "473--477",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - HER-2/neu and fibrinolytic factors in human breast cancer

AU - Tommasi, S.

AU - Rella, C.

AU - Giannella, C.

AU - Quaranta, M.

AU - Schittulli, F.

AU - Paradiso, A.

AU - Coviello, M.

AU - De Lena, M.

PY - 1994

Y1 - 1994

N2 - HER-2/neu status and t-PA, u-PA, and PAI-1 cytosol content were evaluated in 88 primary breast cancer patients to determine the relationships between these parameters. HER-2/neu was amplified in 24% (20/84) of tumor samples and overexpressed in 28% (14/50). In the overall series, median t-PA, u-PA and PAT-1 contents, measured by the enzyme-linked immunoassay (ELISA), resulted in 1.7, 1.1 and 1.0 ng/mg cytosol protein (cyt prot), respectively. HER-2/neu overexpressed cases showed higher u-PA levels than those normally expressed whereas t-PA and PAI-1 levels did not vary in HER-2/neu altered and non altered cases. The t-PA levels did not differ in cases with or without HER-2/neu alterations, when separately considering the node-negative and node-positive cases. A significant relationship between t-PA levels and HER-2/neu alterations was observed only in the ER+ tumors: t-PA levels were lower in amplified and overexpressed cases (1.4 versus 2.5 ng/mg cyt prot in amplified and single copy gene, respectively; 1.6 versus 2.3 ng/mg cyt prot in overexpressed and normally expressed cases, respectively). Therefore, t-PA and HER-2/neu could provide additional prognostic information for ER-negative patients.

AB - HER-2/neu status and t-PA, u-PA, and PAI-1 cytosol content were evaluated in 88 primary breast cancer patients to determine the relationships between these parameters. HER-2/neu was amplified in 24% (20/84) of tumor samples and overexpressed in 28% (14/50). In the overall series, median t-PA, u-PA and PAT-1 contents, measured by the enzyme-linked immunoassay (ELISA), resulted in 1.7, 1.1 and 1.0 ng/mg cytosol protein (cyt prot), respectively. HER-2/neu overexpressed cases showed higher u-PA levels than those normally expressed whereas t-PA and PAI-1 levels did not vary in HER-2/neu altered and non altered cases. The t-PA levels did not differ in cases with or without HER-2/neu alterations, when separately considering the node-negative and node-positive cases. A significant relationship between t-PA levels and HER-2/neu alterations was observed only in the ER+ tumors: t-PA levels were lower in amplified and overexpressed cases (1.4 versus 2.5 ng/mg cyt prot in amplified and single copy gene, respectively; 1.6 versus 2.3 ng/mg cyt prot in overexpressed and normally expressed cases, respectively). Therefore, t-PA and HER-2/neu could provide additional prognostic information for ER-negative patients.

KW - Breast cancer

KW - Fibrinolytic factors

KW - HER-2/neu

UR - http://www.scopus.com/inward/record.url?scp=0028029396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028029396&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028029396

VL - 5

SP - 473

EP - 477

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -